Understanding the Significance of 3,600% Improvement in Overall Survival
With reference to this Press Release:
It indicates that the 1 year Overall Survival is improved by 3,600% over Standard of Care
Let's put this in perspective: Hypothetically,
If you have 1,000 patients with mTNBC. With Standard of Care, let's say that after 1 year, 980 on average die and 20 remain. (This is for example purposes. I have no idea how many typically die and at what stage this decline begins at.)
A 3,600% improvement would make it such that, if treatment with Leronlimab was implemented, then 36 x 20 = 720. 720 would remain and 280 would die.
If fewer people than 980 typically die out of 1,000 with mTNBC, lets say 972 die and 28 remain. Then a 3,600% improvement resulting from treatment with Leronlimab leads to 36 x 28 = 1,000. Every person treated with Leronlimab survives the full year.
As I understand mTNBC, I think with Standard of Care, the average OS overall survival is about 6 months. The vast majority don't make it much past that. So, with SOC, out of a 1,000 with mTNBC, maybe 7 would still remain. Now with Leronlimab, 36 x 7 or 252 would remain and 748 would likely live much longer than they otherwise would have if Leronlimab were not used. IMO, the FDA should look very favorably on this data.
It will be very interesting to see what the 2 year, 3 year, 4 year and 5 year overall survivability will be as the time comes. This is an amazing data point and I think we will get BTD because of this.
This is a link to a post which I did comparing our mTNBC trials to Paclitaxel and the outlook for Leronlimab in treating mTNBC:
https://old.reddit.com/r/CYDY/comments/pd2vrb/my_thoughts_on_the_possibility_of_btd_for_ll_on/
Posted Nov 8, 2021, 3:47 AM UTC · edited